single-pathway drugs weight loss tirzepatide A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). The results: ✓ Tirzepatide: 20.2% ✓ Semaglutide: 13.7% weight loss But weight loss isn't the Tirzepatide for Weight Loss: Physician-Guided

Excessively rapid weight loss can increase risks of gallstones, muscle loss, and nutritional deficiencies, so your healthcare provider should monitor your weight loss trajectory and adjust treatment accordingly

Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed

We observed doses of semaglutide that reduced alcohol-appropriate responding without affecting response rates, suggesting that the interoceptive effects are not driven by changes in food-seeking motivation

It is a tool, not a solution

Mitochondrial glutathione in cellular redox homeostasis and disease manifestation